Diagnostic role of combined determination of serum IP-10，Gas6 and CHI3L1 for liver fibrosis in patients with chronic hepatitis B

doi:10.3969/j.issn.1673-8640.2026.01.003

Abstract

Abstract:

Objective To investigate the levels of serum interferon-gamma-induced protein-10（IP-10），growth arrest-specific gene 6（Gas6）and chitinase 3-like protein 1（CHI3L1）in patients with chronic hepatitis B （CHB），and to investigate their clinical significance. Methods A total of 148 patients with CHB（CHB group）and 148 healthy subjects（healthy control group）were enrolled from Nanyang Central Hospital from May 2022 to May 2024. The CHB patients were classified into mild inflammation（G1-G2 stage）group（69 cases）and severe inflammation（G3-G4 stage）group（79 cases）according to the degree of liver inflammation. The CHB patients were classified into significant liver fibrosis（S2-S4 stage）group（80 cases）and non-significant liver fibrosis（S1 stage）group（68 cases）according to the degree of liver fibrosis. The clinical data and the determination results of liver function indicators [alanine aminotransferase（ALT），aspartate aminotransferase（AST），total bilirubin（TB），albumin（Alb）] were collected，and the levels of serum IP-10，Gas6 and CHI3L1 were determined. Spearman correlation analysis was used to evaluate the correlation between the levels of IP-10，Gas6 and CHI3L1 in CHB patients and the degrees of liver inflammation and liver fibrosis. Multivariate Logistic regression analysis was used to analyze the influencing factors of significant liver fibrosis in CHB patients. Receiver operating characteristic（ROC）curve was used to evaluate the efficacy of IP-10，Gas6 and CHI3L1 in diagnosing significant liver fibrosis in CHB patients. Results The levels of ALT，AST，TB，IP-10 and CHI3L1 in CHB group were higher than those in healthy control group（P<0.001），while the levels of Alb and Gas6 were lower than those in healthy control group（P<0.001）. The serum IP-10 and CHI3L1 levels in severe inflammation group were higher than those in mild inflammation group（P<0.001），and the serum Gas6 level was lower than that in mild inflammation group（P<0.001）. The serum IP-10 and CHI3L1 levels in significant liver fibrosis group were higher than those in non-significant liver fibrosis group（P<0.001），and the serum Gas6 level was lower than that in non-significant liver fibrosis group（P<0.001）. The serum IP-10，CHI3L1 and liver inflammation degree，liver fibrosis degree in CHB patients were positively correlated（P<0.05），while the serum Gas6 was negatively correlated with liver inflammation degree，liver fibrosis degree（P<0.05）. Elevated IP-10 and CHI3L1 and decreased Gas6 were risk factors for significant liver fibrosis in CHB patients [odds ratios（OR）were 5.832，4.774 and 0.467，95% confidence intervals（CI）were 2.611-13.026，2.704-8.428 and 0.328-0.665，P<0.001]. The areas under curves（AUC）of single and combined determinations of serum IP-10，Gas6 and CHI3L1 for diagnosing significant liver fibrosis in CHB patients were 0.818，0.822，0.734 and 0.918，respectively. Conclusions The combined determination of serum IP-10，Gas6 and CHI3L1 has a high diagnostic value for significant liver fibrosis in CHB patients，which may be used for evaluating the degree of liver fibrosis in CHB patients.

Key words: Interferon-gamma-induced protein-10, Growth arrest-specific gene 6, Chitinase 3-like protein 1, Liver fibrosis, Chronic hepatitis B

CLC Number:

R446.1

WANG Likun, LI Zhe, ZHANG Meng, NIU Junqiang, ZHANG Xiaohu. Diagnostic role of combined determination of serum IP-10，Gas6 and CHI3L1 for liver fibrosis in patients with chronic hepatitis B[J]. Laboratory Medicine, 2026, 41(1): 14-19.

Figures/Tables 8

References 19

[1]	YANG N, FENG J, ZHOU T, et al. Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients[J]. J Med Virol, 2018, 90(7):1240-1245. DOI PMID
[2]	汪蕾, 陈晨, 华喜梅, 等. 血清β-arrestin 2、HIF-1a及CA125联合预测慢性乙型肝炎肝纤维化的价值[J]. 肝脏, 2024, 29(5):521-525.
[3]	SU Z, CHEN J, ZHANG J, et al. Circulating IL^-1β,IL^-17,and IP-10 as potential predictors of hepatitis B virus infection prognosis[J]. J Immunol Res, 2022, 2022:5202898.
[4]	RIZZI M, TONELLO S, D'ONGHIA D, et al. Gas6/TAM axis involvement in modulating inflammation and fibrosis in COVID-19 patients[J]. Int J Mol Sci, 2023, 24(2):951. DOI URL
[5]	WANG S, HU M, QIAN Y, et al. CHI3L1 in the pathophysiology and diagnosis of liver diseases[J]. Biomed Pharmacother, 2020, 131:110680. DOI PMID
[6]	中华医学会肝病学分会, 中华医学会感染病学分会. 慢性乙型肝炎防治指南(2022年版)[J]. 中华临床感染病杂志, 2022, 15(6):401-427.
[7]	JIANG Y, HUANG F, CHAI X, et al. The role of IP-10 and its receptor CXCR3 in early pregnancy[J]. Mol Immunol, 2021,140:59-69.
[8]	WANG Y, HU Y, ZHANG X, et al. IP-10 interferes with the antiviral response of direct-acting antiviral agents for hepatitis C virus infection[J]. Front Public Health, 2022, 10:911551. DOI URL
[9]	CHEN Y, WANG J, LIU C, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19[J]. Mol Med, 2020, 26(1):97. DOI PMID
[10]	SALGÜERO S, MEDRANO L M, GONZÁLEZ-GARCÍA J, et al. Plasma IP-10 and IL-6 are linked to Child-Pugh B cirrhosis in patients with advanced HCV-related cirrhosis:a cross-sectional study[J]. Sci Rep, 2020, 10(1):10384. DOI
[11]	DORAN A C, YURDAGUL A Jr, TABAS I. Efferocytosis in health and disease[J]. Nat Rev Immunol, 2020, 20(4):254-267. DOI PMID
[12]	NEPAL S, TIRUPPATHI C, TSUKASAKI Y, et al. STAT6 induces expression of Gas6 in macrophages to clear apoptotic neutrophils and resolve inflammation[J]. Proc Natl Acad Sci U S A, 2019, 116(33):16513-16518. DOI URL
[13]	YAO Z, QI W, ZHANG H, et al. Down-regulated GAS6 impairs synovial macrophage efferocytosis and promotes obesity-associated osteoarthritis[J]. Elife, 2023, 12:e83069. DOI URL
[14]	SMIRNE C, RIGAMONTI C, DE BENEDITTIS C, et al. Gas6/TAM signaling components as novel biomarkers of liver fibrosis[J]. Dis Markers, 2019, 2019:2304931.
[15]	许才红, 宋晨, 钟宏文. 血清FIB-4、CHI3L1、GP73、AFP联合检测在乙型肝炎肝硬化鉴别诊断中的价值[J]. 中国医学创新, 2024, 21(5):122-126.
[16]	BAO J, OUYANG Y, QIAO L, et al. Serum CHI3L1 as a biomarker for non-invasive diagnosis of liver fibrosis[J]. Discov Med, 2022, 33(168):41-49. PMID
[17]	朱娅琪. 血清CHI3L1、CA19-9、GP73水平联合检测在肝硬化鉴别诊断中的价值[J]. 中国民康医学, 2024, 36(7):139-141.
[18]	苗亚琼, 郭黎英, 徐赛赛, 等. 血清PIVKA-Ⅱ、CHI3L1、TFF-1水平在原发性肝癌患者中的变化及临床意义[J]. 承德医学院学报, 2024, 41(1):30-33.
[19]	卢瑾, 闻名, 唐情容, 等. 血清GP73、CHI3L1表达与慢性乙型肝炎患者肝纤维化及病理变化程度的关系[J]. 实用医学杂志, 2024, 40(11):1586-1591.

组别	例数	性别		年龄/岁	饮酒史/例	吸烟史/例	ALT/ （U·L^-1）	AST/ （U·L^-1）	TB/ （μ mol·L^-1）	Alb/ （g·L^-1）
组别	例数	男/例	女/例	年龄/岁	饮酒史/例	吸烟史/例	ALT/ （U·L^-1）	AST/ （U·L^-1）	TB/ （μ mol·L^-1）	Alb/ （g·L^-1）
CHB组	148	75	73	51.35±6.08	77	76	82.44±8.32	88.35±8.87	25.88±4.25	28.22±3.34
正常对照组	148	72	76	50.28±5.22	75	70	20.33±4.38	22.74±5.21	8.92±3.51	40.84±3.46
统计值		0.122		1.624	0.054	0.487	80.362	77.592	37.432	31.925
P值		0.727		0.105	0.816	0.485	<0.001	<0.001	<0.001	<0.001

组别	例数	性别		年龄/岁	饮酒史/例	吸烟史/例	ALT/ （U·L^-1）	AST/ （U·L^-1）	TB/ （μ mol·L^-1）	Alb/ （g·L^-1）
组别	例数	男/例	女/例	年龄/岁	饮酒史/例	吸烟史/例	ALT/ （U·L^-1）	AST/ （U·L^-1）	TB/ （μ mol·L^-1）	Alb/ （g·L^-1）
CHB组	148	75	73	51.35±6.08	77	76	82.44±8.32	88.35±8.87	25.88±4.25	28.22±3.34
正常对照组	148	72	76	50.28±5.22	75	70	20.33±4.38	22.74±5.21	8.92±3.51	40.84±3.46
统计值		0.122		1.624	0.054	0.487	80.362	77.592	37.432	31.925
P值		0.727		0.105	0.816	0.485	<0.001	<0.001	<0.001	<0.001

组别	例数	IP-10/（pg·mL^-1）	Gas6/（pg·mL^-1）	CHI3L1/（ng·mL^-1）
CHB组	148	118.55±30.23	205.49±25.38	73.59±20.28
正常对照组	148	85.34±28.12	234.55±25.81	58.37±10.24
t值		9.786	9.767	8.150
P值		<0.001	<0.001	<0.001

组别	例数	IP-10/（pg·mL^-1）	Gas6/（pg·mL^-1）	CHI3L1/（ng·mL^-1）
CHB组	148	118.55±30.23	205.49±25.38	73.59±20.28
正常对照组	148	85.34±28.12	234.55±25.81	58.37±10.24
t值		9.786	9.767	8.150
P值		<0.001	<0.001	<0.001

组别	例数	IP-10/（pg·mL^-1）	Gas6/（pg·mL^-1）	CHI3L1/（ng·mL^-1）
轻度炎症组	148	109.43±20.23	219.19±12.33	65.97±9.37
重度炎症组	148	126.52±18.12	193.52±20.42	80.24±10.66
t值		5.421	9.092	8.592
P值		<0.001	<0.001	<0.001